UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~April 201, 2026

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)




Delaware	000-30833	04-3110160
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation)	File number)	Identification No.)

40 Manning Road

Billerica, MA 01821

(Address of principal executive offices) (Zip Code)

(978) 663-3660

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share	BRKR	The Nasdaq Global Select Market
6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share	BRKRP	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 5 –- Corporate Governance and Management

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~Retirement~~(d) Election of New Director

On ~~February~~March 1627, 2026, ~~Dr. Cynthia M. Friend informed~~ the Board of Directors (the “Board”) of Bruker Corporation (the “Company”) ofapproved ~~her~~an ~~decision~~increase ~~not~~in tothe ~~stand~~number ~~for~~of ~~re-election~~directors asto aexpand ~~Class II director when her current term expires at~~ the ~~Company’s~~size ~~2026 Annual Meeting~~ of ~~Stockholders~~the ~~(“2026~~Board ~~Annual~~by ~~Meeting”).~~one ~~Dr.~~director ~~Friend’s~~to ~~decision~~a istotal ~~not~~of ~~due~~twelve todirectors, ~~any disagreement~~ with ~~the~~such ~~Company~~additional ondirector ~~any~~assigned ~~matter relating~~ to ~~its~~Class ~~operations~~III, ~~policies, or practices~~ and ~~she~~appointed ~~intends~~Thierry toL. ~~continue~~Bernard to ~~serve~~fill asthe anewly ~~director~~created ~~for~~vacancy on the ~~remainder~~Board, effective as of ~~her~~April ~~current~~1, ~~term~~2026. DrMr. ~~Friend~~Bernard ~~has~~will ~~served~~initially onserve ~~the Board since May 2016 and currently serves~~ as a ~~member~~director ofuntil the ~~Board’s~~2027 ~~Compensation~~Annual ~~Committee~~Meeting of Stockholders.

OnMr. ~~February~~Bernard ~~19,~~currently ~~2026,~~serves ~~Jack~~as ~~Phillips~~Chief ~~stepped~~Executive ~~down~~Officer as(“CEO”) aand ~~Class~~Managing ~~III~~Director ~~member~~ of ~~the~~QIAGEN ~~Board~~N.V. ~~and~~(NYSE: ~~the~~QGEN) ~~Board~~(“QIAGEN”). ~~immediately~~In ~~thereafter~~November ~~re-elected~~2025, ~~him~~QIAGEN asannounced a ~~Class~~CEO IItransition ~~director~~plan whereby Mr. ~~For~~Bernard ~~all~~will ~~purposes,~~step ~~Mr.~~down ~~Phillips’~~as ~~service~~CEO onand ~~the~~Managing ~~Board~~Director once his successor is ~~deemed~~appointed. Mr. Bernard joined QIAGEN in February 2015 to ~~have~~lead ~~continued,~~its ~~uninterrupted~~growing molecular diagnostics business and ~~unchanged~~was ~~(including~~named ~~with~~Chief ~~respect~~Executive toOfficer ~~compensation~~in March 2020 after serving in this role on an interim basis since October 2019 and ~~benefits)~~became a member of its managing board in 2021. Previously, ~~since~~he ~~January~~held 1roles of increasing responsibility during 15 years with bioMérieux SA, ~~2026~~most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the ~~date~~Greater ~~that~~China MrRegion. ~~Phillips~~He ~~first~~also ~~joined~~held senior management roles in several other leading international companies. In March 2023, he was named Chair of the AdvaMedDx Board. Asof Directors, a ~~newly~~U.S. ~~appointed~~industry ~~Class~~trade ~~II director~~association, and joined the board of directors of Neogen Corporation (NASDAQ: NEOG) in 2024. Mr. ~~Phillips~~Bernard ~~will~~has ~~stand~~earned ~~for~~degrees ~~re-election~~and atcertifications from Sciences Po, LSE, the ~~2026~~College ~~Annual~~of ~~Meeting~~Europe, Harvard Business School, Centro de Comercio Exterior de Barcelona and has been appointed Conseiller du Commerce Extérieur by the French government.

~~Section~~Mr. 8Bernard’s compensation for services as a director will be consistent with that of the other non-employee ~~Other~~directors ~~Events~~of the Company, as described under “Director Compensation” in the Company’s definitive proxy statement with respect to the 2025 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on April 11, 2025. There are no other arrangements or understandings between Mr. Bernard and any other person pursuant to which he was elected as a director, and Mr. Bernard is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K.

~~Item~~The Company will file an amended Form 8-K to disclose Mr.~~01.~~ ~~Other~~Bernard's ~~Events~~committee assignments once determined.

~~The~~A ~~Board~~copy of ~~Directors~~the ofpress ~~Bruker~~release ~~Corporation~~announcing ~~declared~~Mr. ~~a quarterly cash dividend on the Company~~Bernard's ~~common~~appointment ~~stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on February 19, 2026, and~~ is ~~payable~~attached ~~April 7, 2026,~~ to ~~shareholders~~this ofreport ~~record~~as atExhibit ~~the close of business on March 23, 2026~~99.1.

Section 9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.


(d)	Exhibits.

	Number	Description

	99.1	Press release dated April 1, 2026.
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRUKER CORPORATION(Registrant)
Date: February 20, 2026	By:	/s/ THOMAS M. BURES
Date: April 1, 2026	By:	/s/ THOMAS M. BURES
		Thomas M. Bures
		Chief Accounting Officer

Filing Compare · BRUKER CORP